Table 1 Linear regression analysis to identify influencing factor of patent citation
From: The global patent landscape of emerging infectious disease monkeypox
Related categories | Unary linear analysis | Multivariate linear analysis | ||||
|---|---|---|---|---|---|---|
Odds Ratio for citation | 95% CI | P-value | Odds Ratio for citation | 95% CI | P-value | |
Year of publication | 0.420 | ( 0. 174 ∼ 0.666 ) | 0.001*** | 0.451 | ( 0. 167 ∼ 0.734 ) | 0.002** |
Inventors | 0.500 | (−0.358 ∼ 1.358 ) | 0.253 | −0.416 | (− 1.202 ∼ 0.370 ) | 0.299 |
Claims | −0. 101 | ( −0.262 ∼ 0.059 ) | 0.216 | 0.045 | ( −0. 100 ∼ 0. 191 ) | 0.539 |
IPC | 0. 143 | ( −0.070 ∼ 0.355 ) | 0. 188 | 0.238 | ( 0.020 ∼ 0.456 ) | 0.032* |
Non-patent citations | 0.450 | ( 0.411 ∼ 0.489 ) | 0.000*** | 0.382 | ( 0.340 ∼ 0.424 ) | 0.000*** |
Citation literature | 0.403 | ( 0.294 ∼ 0.511 ) | 0.000*** | 0.511 | ( 0.012 ∼ 0.230 ) | 0.029* |
Applicant | 1.293 | ( −0.097 ∼ 2.682 ) | 0.068 | 0.316 | (− 1.061 ∼ 1.693 ) | 0.653 |
Type of patentees | ||||||
Commercial (Reference category) | 1.000 | 1.000 | ||||
Academic | 0.639 | ( −3.974 ∼ 5.251 ) | 0.786 | 0. 166 | ( −4. 180 ∼ 4.512 ) | 0.940 |
Government | 1.992 | ( −4.577 ∼ 8.561 ) | 0.552 | −3.656 | ( −9.995 ∼ 2.683 ) | 0.258 |
Academic &Commercial | −6.511 | (−16.336 ∼ 3.315 ) | 0. 194 | −7.266 | (− 16.046 ∼ 1.513 ) | 0. 105 |
Individual | −6.766 | (−17.513 ∼ 3.981 ) | 0.217 | −2.430 | (− 12.622 ∼ 7.762 ) | 0.640 |
Academic &Government | −6.009 | (−32.573 ∼ 20.554 ) | 0.657 | − 1.505 | (−25.008 ∼ 21.998 ) | 0.900 |
Government &Commercial | −6.486 | (−35.166 ∼ 22.195 ) | 0.657 | − 1.399 | (−26.590 ∼ 23.792 ) | 0.913 |
Countries of patentees | ||||||
US (Reference category) | 1.000 | 1.000 | ||||
FR | −8.378 | (−15.961 ∼ −0.795 ) | 0.030* | −4. 182 | (− 11.087 ∼ 2.722 ) | 0.235 |
DK | −2.234 | (− 10.020 ∼ 5.552 ) | 0.574 | −2.865 | (− 11.435 ∼ 5.706 ) | 0.512 |
GB | −10.557 | (−20.179 ∼ −0.935 ) | 0.032* | −2. 155 | (− 10.874 ∼ 7. 168 ) | 0.650 |
CA | −7.445 | (− 16.825 ∼ 1.936 ) | 0. 120 | − 1.832 | (− 11.479 ∼ 7.210 ) | 0.691 |
Other countries | −6.838 | (− 11.660 ∼ −2.015 ) | 0.005** | −3.426 | ( −7.968 ∼ 1. 116 ) | 0. 139 |
Technological types | ||||||
Treatment (Reference category) | 1.000 | 1.000 | ||||
Other technologies | −5.537 | (− 11.700 ∼ 0.626 ) | 0.078 | −2.061 | ( −7.635 ∼ 3.513 ) | 0.468 |
Testing | −9.612 | (-18.949 ∼ −0.275 ) | 0.044* | −2.948 | (− 11.663 ∼ 5.767 ) | 0.507 |
Vaccine | −5.004 | ( −10.419 ∼ 0.412 ) | 0.070 | −3.226 | ( −8.791 ∼ 2.340 ) | 0.256 |
Basic research | −2. 140 | ( −7. 145 ∼ 2.866 ) | 0.402 | 0.666 | ( −4.832 ∼ 6. 163 ) | 0.812 |
Within the validity period of patent protection | ||||||
No (Reference category) | 1.000 | 1.000 | ||||
Yes | 7.849 | (−4.382 ∼ 11.316 ) | 0.000*** | 3. 109 | ( −0.650 ∼ 6.868 ) | 0. 105 |
Indeterminate | −4.801 | ( −10.578 ∼ 0.976 ) | 0. 103 | −3.696 | ( −9.703 ∼ 2.310 ) | 0.228 |
Jurisdiction district | ||||||
US (Reference category) | 1.000 | 1.000 | ||||
WO | − 18.389 | (−23.983∼−12.794 ) | 0.000*** | − 10.022 | (− 15.624 ∼ −4.420 ) | 0.000*** |
EP | − 12.777 | ( −18.783 ∼−6.771 ) | 0.000*** | −3.516 | (− 9.325 ∼ 2.294 ) | 0.235 |
JP | −23. 178 | (−29.433 ∼−16.923 ) | 0.000*** | − 13.045 | (− 19.203 ∼ −6.888 ) | 0.000*** |
AU | −24.825 | (−31.379 ∼ −18.270 ) | 0.000*** | − 11.743 | (− 18.041 ∼ −5.446 ) | 0.000*** |
CN | −24. 182 | (−31.765 ∼ − 16.599 ) | 0.000*** | − 11.426 | (− 18.577 ∼ −4.276 ) | 0.002** |
CA | −26. 118 | (−33.956 ∼ − 18.280 ) | 0.000*** | − 12.462 | (− 19.835 ∼ −5.088 ) | 0.001*** |
IN | −26. 118 | (−35.897 ∼ − 16.339 ) | 0.000*** | − 10.729 | ( −20.015 ∼ − 1.442 ) | 0.024* |
KR | −24.298 | (−34.252 ∼ − 14.343 ) | 0.000*** | − 11. 109 | ( −20.471 ∼ − 1.747 ) | 0.020* |
Other areas | −25. 140 | (−29.773 ∼ −20.507 ) | 0.000*** | − 12. 144 | (− 16.842 ∼ −7.446 ) | 0.000*** |